Investor's Business Daily
AppLovin Stock Rides Swarm Of Setups Beyond Just Mining, Medical Names
📊
AI Sentiment
Positive
7/10
- Home
- RIGL
as of 12-05-2025 4:00pm EST
$48.92
+$1.54
+3.25%
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Chart Type:
Time Range:
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 537.6M | IPO Year: | 2000 |
| Target Price: | $43.20 | AVG Volume (30 days): | 638.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 6.20 | EPS Growth: | 2698.26 |
| 52 Week Low/High: | $14.63 - $52.24 | Next Earning Date: | 11-04-2025 |
| Revenue: | $282,076,000 | Revenue Growth: | 79.13% |
| Revenue Growth (this year): | 65.53% | Revenue Growth (next year): | 0.22% |
AI-Powered RIGL Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 67.32%
67.32%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Rigel Pharmaceuticals Inc. News
RIGL Breaking Stock News: Dive into RIGL Ticker-Specific Updates for Smart Investing
Zacks
Should Value Investors Buy Rigel Pharmaceuticals (RIGL) Stock?
📈
AI Sentiment
Highly Positive
8/10
Business Wire
GE HealthCare builds on a century of innovation to shape the future of radiology at RSNA 2025
📈
AI Sentiment
Highly Positive
8/10
Financial Times
Airlines avert travel chaos after rushing to install software fix on A320 jets
âž–
AI Sentiment
Neutral
5/10
24/7 Wall St.
3 Stocks That Outperformed Palantir in 2025. Can They Repeat in 2026?
📈
AI Sentiment
Highly Positive
8/10
Compare RIGL vs Leading Stocks
See how RIGL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RIGL Rigel Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.